LIROH - Liraglutide for Obesity in HIV

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
ObesityHIV Infections
Interventions
DRUG

Liraglutide

"Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration"

Trial Locations (1)

3935

RECRUITING

Africa Health Research Institute Clinical Trials Unit, Mtubatuba

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Brigham and Women's Hospital

OTHER